The trend: Consumer interest in peptides—the amino acid building blocks of proteins—is reaching a fever pitch.

• Search interest in peptides has recently overtaken "Ozempic," according to US Google Trends data analyzed by Sherwood News.
• Roughly 1,000 Chinese vendors are now exporting unregulated peptides directly to Western consumers for skincare, weight loss, and muscle building via messaging apps and online platforms, per a January Financial Times report.
• For context, while the category includes FDA-approved heavyweights like insulin and semaglutide, a massive unregulated market is emerging.

Driving the trend: Influencers and celebrities are touting peptides on social media, often fueling the trend with discount codes for online retailers and specialized suppliers.

• Joe Rogan has credited peptides as being instrumental in his injury recovery, endorsing Ways2Well, an online clinic that sells peptides. The company has a video of Rogan’s endorsement on the front page of its website.
• Various fitness influencers, chiefly on TikTok and YouTube, hype up BPC-157, a popular peptide that’s sometimes touted as a "cure-all" for tendonitis, muscle tears, and overall longevity.
• On platforms like TikTok, vendors in China and elsewhere advertise dozens of peptide types shipped to the US for as little as $5 per vial, per CNN.

The problem: Market confusion is rising as consumers navigate a landscape of unapproved products and inconsistent messaging from niche sellers and major retailers alike.

• For example, even Amazon listings for BPC-157 are difficult to interpret. Its Rufus AI assistant, listed next to a BPC-157 product from a third-party manufacturer, notes that BPC-157 research exists primarily in laboratory and animal studies, with limited human clinical trials.
• Other, far lesser-known online sites run peptide ads on social media that direct users into WhatsApp chats to drive purchases.
• Some sellers classify peptides as “research chemicals,” which creates a legal gray area that bypasses the FDA’s stricter pharmaceutical approval process.

Implications for healthcare brands: Recent manufacturing facility acquisitions by Hims & Hers and Noom signal that the peptide boom is no longer just "internet hype"—it’s a business priority. While peptides are often compared to GLP-1s, peptide sellers cannot expect the same explosive growth without bridging the gap between the unregulated market and the clinical-grade evidence consumers expect from modern weight loss therapies.

In an emerging field, brands risk driving customers away with potentially dangerous products just as easily as they attract them through attention-grabbing campaigns and word-of-mouth testimonials. As regulatory scrutiny of online health claims intensifies, credible brands must be transparent in their marketing claims and be prepared to answer questions about how their product works and the testing behind it. Brands can also secure early wins by using their provider networks to educate consumers on different peptide quality, helping distinguish safe products from risky online alternatives.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.